We are a SPECIALTY PHARMACEUTICAL COMPANY

SOLVING THE UNSOLVED

We are on a mission to improve public health globally by providing novel therapies for unmet medical needs across ophthalmology, dermatology, and oral care. 

What we do

For over two decades, our team has collaborated with major US universities to invent  a technology platform that modulates metal ions in disease pathways. We have a single molecule platform with broad applicability across multiple indications. 

eye icon

Ophthamology

We are developing eye drops as a treatment for  band keratopathy patients. Additionally, our team is advancing a topical treatment to improve vision in cataract patients.  

dermatology icon

Dermatology

We are developing an anti-inflammatory dermal lotion to topically treat lower leg edema and stasis dermatitis in patients suffering from Chronic Venous Insufficiency.

oral care icon

Oral Care

We have developed a toothpaste that is approved in Europe for the treatment & prevention of gingivitis, periodonititis & caries. This product is sold under the LIVFRESH brand.

eye icon

Ophthamology

We are developing eye drops as a treatment for  band keratopathy patients. Additionally, our team is advancing a topical treatment to improve vision in cataract patients.  

dermatology icon

Dermatology

We are developing an anti-inflammatory dermal lotion to topically treat lower leg edema and stasis dermatitis in patients suffering from Chronic Venous Insufficiency.

oral care icon

Oral Care

We have developed a toothpaste that is approved in Europe for the treatment & prevention of gingivitis, periodonititis & caries. This product is sold under the LIVFRESH brand.

Generating New Ideas. Solving Big Problems

The L1220 compound is effective against inflammation, metalo lipid-protein aggregates, and biofilms. Livionex technology enables a unique metal modulation pathway to address multiple disease modalities.

Research Studies

Patents & Applications

Partnerships & Collaborations

Approval

Origins story image

Our Origins

Livionex originated because of one man’s desire to restore his father’s vision. Rajiv Bhushan, one of our founders, formulated eye drops to treat his father, Arya, who was suffering from cataracts, photophobia, and dry AMD. Within six months of use, Arya was able to thread a needle. Having defied the odds, ophthalmologists at premier universities could not believe Arya’s vision improvement. Soon after, Rajiv partnered with serial entrepreneur, Amit Goswamy, to commercialize the eye drops and gain  regulatory approvals. Their ultimate goal was, and still is, to improve the vision of millions.

Over the years, Rajiv and Amit discovered that the technology underlying the eye drops could be applied to other diseases, including Chronic Venous Insufficiency and Periodontitis. Livionex soon became a pharmaceutical company specializing in ophthalmology, dermatology, and oral care.

CLINICAL STAGES

L1220-E eye drops have gained FDA approval to proceed to a single claim enabling Phase III trial as the first topical treatment of Band Keratopathy. Additionally, a topical eye drop is in advanced clinical development to restore vision loss in patents with early to moderate Cataracts. Additionally, we plan to file an IND and initiate a Phase I/II trial for our dermal therapy. The dermal lotion is targeted as a treatment for Lower Leg Edema and Stasis Dermatitis due to Chronic Venous Insufficiency (CVI).

  • Ophthalmology (Initiating Phase 3)
  • Dermatology (Initiating Phase 2)

COLLABORATIONS & PARTNERSHIPS

The company is fortunate to partner and collaborate with industry leaders and leading research institutions. 

ACADEMIC AWARDS & GRANTS

Academic awards & grants

UNIVERSITY PARTNERSHIPS

University partnerships livionex
computer screen image

Free iron and calcium play a key role in oxidative stress and pathways leading to multiple diseases. The Company’s proprietary small molecule technology modulates intracellular metal ions, such as calcium and iron in the body. While metal chelation is a well-understood scientific process, its therapeutic effectiveness in clinical settings has been limited primarily due to the inability of chelator molecules to permeate across negatively charged biological tissues and cell membranes. Livionex has solved the problem of delivering chelators at therapeutic levels, enabling drug development across multiple areas of research. 

Our Team

With decades of experiences spanning across diverse industries and academia, the Livionex team is comprised of the best and brightest.

Amit Goswamy

CEO

Serial entrepreneur  with multiple exits of VC-backed companies. Indian Institute of Technology & Stanford MBA.

Rajiv Bhushan

CHIEF SCIENTIST

Inventor and experienced researcher with multiple patents in biochemistry and semiconductors. Calcutta University and UC Berkeley.

Richard Trevino, PhD

HEAD OF MANUFACTURING

25+ years of managerial experience in manufacturing for pharmaceutical companies including Amgen, Johnson & Johnson, and Onyx Pharmaceuticals. University of Texas PhD in Biochemistry.

Brian Novy, DDS, FADI, FACD

LEAD CLINICIAN

Past Chair of ADA Council on Scientific Affairs Subcommittee on Caries Management

Jerry Gin, PhD

CHAIRMAN

Founder Oculex Pharma (acquired by Allergan) & ChemTrak (IPO). UC Berkeley PhD in Biochemistry.

Hirsh Goswamy

HEAD OF MARKETING

Marketing executive with track record of launching global brands with exponential growth. Fellow at OnDeck and Member Leader on Forbes Business Council. UC Berkeley.

Tatsuya Kuboi

HEAD OF BUSINESS DEVELOPMENT

Global business executive. Public accounting with KPMG & investment banking with Bank of America Securities. University of Washington & Stanford MBA.

Get in touch.

Have a question? Please fill out the form below, and we will respond to you as soon as possible. Inquiries are typically addressed within 3 business days. Thank you!